Back to Search Start Over

Intussusception after Rotavirus Vaccine Introduction in India

Authors :
Suresh Goyal
Balasubramanian Sundaram
Kulandaivel Murugiah
Sunita Bidari
Prasantajyoti Mohanty
Gagandeep Kang
Rajendra P Gorthi
Mannancheril A Mathew
Vineeta Gupta
Nayana P Nair
Hemant Jain
Suraj Chawla
Hemanthkumar Boopathy
Gopinath Vinayagamurthy
Rajkumar Gupta
Samarasimha N Reddy
Pramod Sharma
Sambandan Kumaravel
Muthukumaran Jagannatham
Mohan D Gupte
Saroj Sathpathy
Ira Praharaj
Raghul Maniam
Ashwitha Shenoy
Jacqueline E Tate
Venkata R Mohan
Girish K C Purushothaman
Geeta Gathwala
Sudhir Babji
Hiranya Mohanty
Jayanta K Goswami
Sowmiya Senthamizh
Vittal Mohan
Madhu Gupta
Umesh D Parashar
Krishna B Goru
Priyadarishini Dorairaj
Tarun J K Jacob
Rashmi Arora
Nirmal Kumar Mohakud
Padmalatha Pamu
Rajib Kumar Ray
Sidhartha Giri
Ashish Wakhlu
Manohar Badur
Suhasini Mekala
Mrutunjay Dash
Rajamani Gurusamy
Varunkumar Thiyagarajan
Bhaskar Reddy
Source :
The New England Journal of Medicine
Publication Year :
2020
Publisher :
Massachusetts Medical Society, 2020.

Abstract

A three-dose, oral rotavirus vaccine (Rotavac) was introduced in the universal immunization program in India in 2016. A prelicensure trial involving 6799 infants was not large enough to detect a small increased risk of intussusception. Postmarketing surveillance data would be useful in assessing whether the risk of intussusception would be similar to the risk seen with different rotavirus vaccines used in other countries.We conducted a multicenter, hospital-based, active surveillance study at 27 hospitals in India. Infants meeting the Brighton level 1 criteria of radiologic or surgical confirmation of intussusception were enrolled, and rotavirus vaccination was ascertained by means of vaccination records. The relative incidence (incidence during the risk window vs. all other times) of intussusception among infants 28 to 365 days of age within risk windows of 1 to 7 days, 8 to 21 days, and 1 to 21 days after vaccination was evaluated by means of a self-controlled case-series analysis. For a subgroup of patients, a matched case-control analysis was performed, with matching for age, sex, and location.From April 2016 through June 2019, a total of 970 infants with intussusception were enrolled, and 589 infants who were 28 to 365 days of age were included in the self-controlled case-series analysis. The relative incidence of intussusception after the first dose was 0.83 (95% confidence interval [CI], 0.00 to 3.00) in the 1-to-7-day risk window and 0.35 (95% CI, 0.00 to 1.09) in the 8-to-21-day risk window. Similar results were observed after the second dose (relative incidence, 0.86 [95% CI, 0.20 to 2.15] and 1.23 [95% CI, 0.60 to 2.10] in the respective risk windows) and after the third dose (relative incidence, 1.65 [95% CI, 0.82 to 2.64] and 1.08 [95% CI, 0.69 to 1.73], respectively). No increase in intussusception risk was found in the case-control analysis.The rotavirus vaccine produced in India that we evaluated was not associated with intussusception in Indian infants. (Funded by the Bill and Melinda Gates Foundation and others.).

Details

ISSN :
15334406 and 00284793
Volume :
383
Database :
OpenAIRE
Journal :
New England Journal of Medicine
Accession number :
edsair.doi.dedup.....bb04b14f216d8565e764110cd4db0c21